- cafead Nov 02, 2023 at 11:32: AM
via Rani Therapeutics and Sangamo Therapeutics have become the latest biotechs to significantly shrink their workforces in order to eke out cash to survive another year.
California-based Rani will lose a quarter of employees as part of a package of measures to extend its cash runway long enough to see top-line results for a phase 2 trial of a teriparatide-containing pill for osteoporosis called RT-102 alongside a phase 1 study of RT-111, a biosimilar of Johnson & Johnson’s Crohn's disease drug Stelara.
article source
California-based Rani will lose a quarter of employees as part of a package of measures to extend its cash runway long enough to see top-line results for a phase 2 trial of a teriparatide-containing pill for osteoporosis called RT-102 alongside a phase 1 study of RT-111, a biosimilar of Johnson & Johnson’s Crohn's disease drug Stelara.
article source